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Abstract  
The successful delivery of drugs across the oral mucosa represents a continuing challenge, as 
well as a great opportunity. Oral transmucosal delivery, especially buccal and sublingual 
delivery, has progressed far beyond the use of traditional dosage forms with novel approaches 
emerging continuously. This review highlights the physiological challenges as well as the 
advances and opportunities for buccal/sublingual drug delivery. Particular attention is given 
to new approaches which can extend dosage form retention time or can be engineered to 
deliver complex molecules such as proteins and peptides. The review will also provide a link 
between the physiology and local environment of the oral cavity in vivo and how this relates 
the performance of transmucosal delivery systems.  
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1. Introduction 
The cost involved both in terms of money and time in the development of a single new 
chemical entity has made it mandatory for pharmaceutical companies to reconsider delivery 
strategies to improve the efficacy of drugs that have already been approved. However, despite 
the tremendous advances in drug delivery, the oral route remains the preferred route for the 
administration of therapeutic agents due to low cost, ease of administration and high level of 
patient compliance. However, significant barriers impose for the peroral administration of 
drugs,  such as hepatic first pass metabolism and  drug degradation within the gastrointestinal 
(GI) tract  prohibiting the oral administration of certain classes of drugs especially biologics 
e.g. peptides and proteins. Consequently, other absorptive mucosae are being considered as 
potential sites for drug administration including the mucosal linings of the nasal, rectal, 
vaginal, ocular, and oral cavity. These transmucosal routes of drug delivery offer distinct 
advantages over peroral administration for systemic drug delivery such as possible bypass of 
the first pass effect and avoidance of presystemic elimination within the GI tract [1]. 
Amongst these, delivery of drugs to the oral cavity has attracted particular attention due to its 
potential for high patient compliance and unique physiological features. Within the oral 
mucosal cavity, the delivery of drugs is classified into two categories: (i) local delivery and 
(ii) systemic delivery either via the buccal or sublingual mucosa. This review examines the 
physiological considerations of the oral cavity in light of systemic drug delivery and provides 
an insight into the advances in oral transmucosal delivery systems. 
2. Overview of the oral mucosa 
The anatomical and physiological properties of oral mucosa had been extensively reviewed 
by several authors [1-3]. The oral cavity comprises the lips, cheek, tongue, hard palate, soft 
palate and floor of the mouth (Figure 1). The lining of the oral cavity is referred to as the oral 
mucosa, and includes the buccal, sublingual, gingival, palatal and labial mucosa. The buccal, 
sublingual and the mucosal tissues at the ventral surface of the tongue accounts for about 
60% of the oral mucosal surface area. The top quarter to one-third of the oral mucosa is made 
up of closely compacted epithelial cells (Figure 2). The primary function of the oral 
epithelium is to protect the underlying tissue against potential harmful agents in the oral 
environment and from fluid loss [4]. Beneath the epithelium are the basement membrane, 
lamina propia and submucosa. The oral mucosa also contains many sensory receptors 
including the taste receptors of the tongue.  
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Three types of oral mucosa can be found in the oral cavity; the lining mucosa is found in the 
outer oral vestibule (the buccal mucosa) and the sublingual region (floor of the mouth) 
(Figure 1). The specialised mucosa is found on the dorsal surface of tongue, while the 
masticatory mucosa is found on the hard palate (the upper surface of the mouth) and the 
gingiva (gums) [5]. The lining mucosa comprises approximately 60%, the masticatory 
mucosa approximately 25%, and the specialized mucosa approximately 15% of the total 
surface area of the oral mucosal lining in an adult human. The masticatory mucosa is located 
in the regions particularly susceptible to the stress and strains resulting from masticatory 
activity. The superficial cells of the masticatory mucosa are keratinized, and a thick lamina 
propia tightly binds the mucosa to underlying periosteum. Lining mucosa on the other hand is 
not nearly as subject to masticatory loads and consequently, has a non-keratinized epithelium, 
which sits on a thin and elastic lamina propia and a submucosa. The mucosa of the dorsum of 
the tongue is specialized gustatory mucosas, which has a well papillated surface; which are 
both keratinized and some non-keratinized [6]. 
 
 Figure 1: Schematic representation of the different linings of mucosa in mouth [7] 
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Figure 2: Schematic diagram of buccal mucosa [8] 
 
3. Physiological barriers for oral transmucosal drug delivery 
The environment of the oral cavity presents some significant challenges for systemic drug 
delivery. The drug needs to be released from the formulation to the delivery site (e.g. buccal 
or sublingual area) and pass through the mucosal layers to enter the systemic circulation. 
Certain physiological aspects of the oral cavity play significant roles in this process, 
including pH, fluid volume, enzyme activity and the permeability of oral mucosa. For drug 
delivery systems designed for extended release in the oral cavity (e.g. mucodhesive systems), 
the structure and turnover of the mucosal surface is also a determinant of performance. Table 
1 provides a comparison of the physiological characteristics of the buccal mucosa with the 
mucosa of the GI tract.  
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Table 1: Comparison of different mucosa [9-12] 
Absorptive 
site 
Estimated 
Surface area 
Percent 
total 
surface 
area 
Local 
pH 
Mean 
fluid 
volume 
(ml) 
Relative 
enzyme 
activity 
Relative 
drug 
absorption 
capacity 
Buccal 100 cm
2
  
(0.01 m
2
) 
0.01 5.8-7.6 0.9 Moderate High 
Stomach 0.1-0.2 m
2
 0.20 1.0-3.0 118 High High 
Small 
Intestine 
100 m
2
 98.76 3.0-4.0 212 High High 
Large 
Intestine 
0.5-1.0 m
2
 0.99 4.0-6.0 187 Moderate Low 
Rectum 200-400 cm
2
  
(0.04 m
2
) 
0.04 5.0-6.0 - Low Low 
 
The principle physiological environment of the oral cavity, in terms of pH, fluid volume and 
composition, is shaped by the secretion of saliva. Saliva is secreted by three major salivary 
glands (parotid, submaxillary and sublingual) and minor salivary or buccal glands situated in 
or immediately below the mucosa. The parotid and submaxillary glands produce watery 
secretion, whereas the sublingual glands produce mainly viscous saliva with limited 
enzymatic activity. The main functions of saliva are to lubricate the oral cavity, facilitate 
swallowing and to prevent demineralisation of the teeth. It also allows carbohydrate digestion 
and regulates oral microbial flora by maintaining the oral pH and enzyme activity [13, 14]. 
The daily total salivary volume is between 0.5 and 2.0 L. However, the volume of saliva 
constantly available is around 1.1 ml, thus providing a relatively low fluid volume available 
for drug release from delivery systems compared to the GI tract. Compared to the GI fluid, 
saliva is relatively less viscous containing 1% organic and inorganic materials. In addition, 
saliva is a weak buffer with a pH around 5.5-7.0. Ultimately the pH and salivary 
compositions are dependant on the flow rate of saliva which in turn depends upon three 
factors: the time of day, the type of stimulus and the degree of stimulation [15]. For example, 
at high flow rates, the sodium and bicarbonate concentrations increase leading to an increase 
in the pH. 
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Saliva provides a water rich environment of the oral cavity which can be favourable for drug 
release from delivery systems especially those based on hydrophilic polymers. However, 
saliva flow decides the time span of the released drug at the delivery site. This flow can lead 
to premature swallowing of the drug before effective absorption occurs through the oral 
mucosa and is a well accepted concept as “saliva wash out”. However, there is little research 
on to what extent this phenomenon affects the efficiency of oral transmucosal delivery from 
different drug delivery systems and thus further research needs to be conducted to better 
understand this effect.   
Drug permeability through the oral (e.g. buccal/sublingual) mucosa represents another major 
physiological barrier for oral transmucosal drug delivery. The oral mucosal thickness varies 
depending on the site as does the composition of the epithelium. The characteristics of the 
different regions of interest in the oral cavity are shown in Table 2. The mucosa of areas 
subject to mechanical stress (the gingiva and hard palate) is keratinized similar to the 
epidermis. The mucosa of the soft palate, sublingual, and buccal regions, however, are not 
keratinized. The keratinized epithelia contain neutral lipids like ceramides and acylceramides 
which have been associated with the barrier function. These epithelia are relatively 
impermeable to water. In contrast, non-keratinized epithelia, such as the floor of the mouth 
and the buccal epithelia do not contain acylceramides and only have small amounts of 
ceramides [16]. They also contain small amounts of neutral but polar lipids, mainly 
cholesterol sulfate and glucosyl ceramides. These epithelia have been found to be 
considerably more permeable to water than keratinized epithelia [17, 18]. 
Table 2: Characteristics of oral mucosa 
Tissue  
[20] 
Structure Thickness 
(µm) [20] 
Turnover 
time 
(days) 
[22] 
Surface 
area (cm
2
) 
± SD [6] 
Permeability 
[19] 
Residence 
time [19] 
Blood 
flow* 
[21] 
Buccal NK 500-600 5-7 50.2 ± 2.9 Intermediate Intermediate 20.3 
Sublingual NK 100-200 20 26.5 ± 4.2 Very good Poor 12.2 
Gingival K 200 - - Poor Intermediate 19.5 
Palatal K 250 24 20.1 ± 1.9 Poor Very good 7.0 
NK is nonkeratinized tissue, K is Keratinized tissue and * In rhesus monkeys (ml/min/100 g 
tissue). 
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Within the oral mucosa, the main penetration barrier exists in the outermost quarter to one 
third of the epithelium [23, 24]. The relative impermeability of the oral mucosa is 
predominantly due to intercellular materials derived from the so-called membrane coating 
granules Q (MCGs) [2]. MCGs are spherical or oval organelles that are 100 - 300 nm in 
diameter and found in both keratinized and non-keratinized epithelia [25]. They are found 
near the upper, distal, or superficial border of the cells, although a few occur near the 
opposite border [25]. Several hypotheses have been suggested to describe the functions of 
MCGs, including membrane thickening, cell adhesion, production of a cell surface coat, cell 
desquamation and as a permeability barrier. Hayward [25] summarised that the MCGs 
discharge their contents into the intercellular space to ensure epithelial cohesion in the 
superficial layers, and this discharge forms a barrier to the permeability of various 
compounds. Cultured oral epithelium devoid of MCGs has been shown to be permeable to 
compounds that do not typically penetrate the oral epithelium [26]. In addition, permeation 
studies conducted using tracers of different sizes have demonstrated that these tracer 
molecules did not penetrate any further than the top 1-3 cell layers. When the same tracer 
molecules were introduced sub-epithelially, they penetrated through the intercellular spaces. 
This limit of penetration coincides with the level where MCGs are observed. This same 
pattern is observed in both keratinized and non-keratinized epithelia [3], which indicates that 
MCGs play a more significant role as a barrier to permeation compared to the keratinisation 
of the epithelia [27]. 
The cells of the oral epithelia are surrounded by an intercellular ground substance called 
mucus, the principle components of which are complexes made up of proteins and 
carbohydrates; its thickness ranging from 40 to 300 μm [28]. In the oral mucosa; mucus is 
secreted by the major and minor salivary glands as part of saliva.  Although most of the 
mucus is water (≈95-99% by weight) the key macromolecular components are a class of 
glycoprotein known as mucins (1-5%). Mucins are large molecules with molecular masses 
ranging from 0.5 to over 20 MDa and contain large amounts of carbohydrate. Mucins are 
made up of basic units (≈400–500 kDa) linked together into linear arrays. These big 
molecules are able to join together to form extended three-dimensional network [29] which 
acts as a lubricant allowing cells to move relative to one another, and may also contribute to 
cell-cell adhesion [14]. At physiological pH, the mucus network carries a negative charge due 
to the sialic acid and sulfate residues and forms a strongly cohesive gels structure that will 
bind to the epithelial cell surface as a gelatinous layer [30-32]. This gel layer is believed to 
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play a role in mucoadhesion for drug delivery systems which work on the principle of 
adhesion to the mucosal membrane and thus extend the dosage form retention time at the 
delivery site.  
Another factor of the buccal epithelium that can affect mucoadhesion of drug delivery 
systems is the turnover time. The turnover time for the buccal epithelium has been estimated 
3-8 days compared to about 30 days for the skin [2] which may change permeability 
characteristics frequently.  
4. Physiological opportunities for oral transmucosal drug delivery 
Despite the physiological challenges, the oral mucosa, due its unique structural and 
physiological properties, offers several opportunities for systemic drug delivery. As the 
mucosa is highly vascularized any drug diffusing across the oral mucosa membranes has 
direct access to the systemic circulation via capillaries and venous drainage and will bypass 
hepatic metabolism. The rate of blood flow through the oral mucosa is substantial, and is 
generally not considered to be the rate-limiting factor in the absorption of drugs by this route 
(Table 2).  
For oral delivery through the GI tract, the drug undergoes a rather hostile environment before 
absorption. This includes a drastic change in GI pH (from pH 1-2 in the stomach to 7-7.4 in 
the distal intestine), unpredictable GI transit, the presence of numerous digestive enzymes 
and intestinal flora [33, 34]. In contrast to this harsh environment of the GI tract, the oral 
cavity offers relatively consistent and friendly physiological conditions for drug delivery 
which are maintained by the continual secretion of saliva. Compared to secretions of the GI 
tract, saliva is a relatively mobile fluid with less mucin, limited enzymatic activity and 
virtually no proteases [35].  
Enzyme degradation in the GI tract is a major concern for oral drug delivery. In comparison, 
the buccal and sublingual regions have less enzymes and lower enzyme activity, which is 
especially favourable to protein and peptide delivery. The enzymes that are present in buccal 
mucosa are believed to include aminopeptidases, carboxypeptidases, dehydrogenases and 
esterases. Aminopeptidases may represent a major metabolic barrier to the buccal delivery of 
peptide drugs. Proteolytic activity has been identified in buccal tissue homogenates from 
various species and a number of peptides have been shown to undergo degradation [36]. 
Bernkop-Schnurch and co-workers [37] studied the peptidase activity on the surface of 
porcine buccal mucosa and found that no carboxypeptidase or dipeptidyl peptidase IV 
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activity was detected on the buccal mucosa, while aminopeptidase N activity was detected 
using Leu-p-nitroanilide. However, this study represents only the surface of procine mucosa 
and hence more research will be required to fully characterize the levels and type of different 
enzymes presents especially in human buccal mucosa. 
The buccal and sublingual routes are the focus for drug delivery via the oral mucosa because 
of the higher overall permeability compared to the other mucosa of the mouth. The effective 
permeability coefficient values reported in the literature across the buccal mucosa for 
different molecules, range from a lower limit of 2.2 × 10
9
 cm/s for dextran 4000 across rabbit 
buccal membrane to an upper limit of 1.5 × 10
5
 cm/s for both benzylamine and amphetamine 
across rabbit and dog buccal mucosa, respectively [2]. The oral mucosa is believed to be 4-
4000 times more permeable than that of skin [24]. Squier and co-workers [38] revealed that 
the permeability of water through the buccal mucosa was approximately 10 times higher, 
whilst in floor of the mouth the permeability was approximately 20 times higher than skin 
(Table 3). In another study by Squier and Hall [39], the permeability constant was calculated 
for water and Horseradish peroxidase across skin and oral mucosal surface (Table 4). 
Table 3: Permeabilities of water for human skin and oral mucosa regions (Adapted from 
Squier and co-workers [38]) 
Region
 a
 Kp (× 10
-7
 ± SEM cm/min) 
Skin
 
 44 ± 4
 b
 
Oral mucosa  
Hard palate 470 ± 27 
Buccal mucosa 579 ± 16 
Lateral border of tongue 772 ± 23 
Floor of mouth 973 ± 33 
a. Human (n=58). 
b. Permeability constant significant compared to oral mucosa at P < 0.05. 
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Table 4: Regional difference in permeability expressed in terms of a uniform permeability 
barrier (Adapted from Squier and Hall [39]) 
Tissue region Thickness (µm ± SEM) Mean Kp expressed in terms of a 
uniform barrier of 100 µm thick 
(± SEM × 10
-7
) 
 Total 
epithelium 
Permeability 
barrier 
Water Horseradish 
peroxidise 
Skin 69 ± 4 16 ± 1 21.1 ± 4.3 9.4 ± 1.8 
Gingiva 208 ± 9 35 ± 4 98.3 ± 16.0 79.5 ± 11.4 
Buccal mucosa 772 ± 20 282 ± 17 173.2 ± 24.6 99.1 ± 10.6 
Floor of mouth 192 ± 7 23 ± 1 1271.3 ± 203.1 331.6 ± 51.9 
 
Drug can be transported across epithelial membranes by passive diffusion, carrier-mediated, 
active transport or other specialized mechanisms. Most studies of buccal absorption indicate 
that the predominant mechanism is passive diffusion across lipid membranes via either the 
paracellular or transcellular pathways (Figure 3) [40-44]; although these may actually be the 
same pathway. The hydrophilic nature of the paracellular spaces and cytoplasm provides a 
permeability barrier to lipophilic drugs but can be favourable for hydrophilic drugs. In 
contrast, the transcellular pathway involves drugs penetrating through one cell and the next 
until entering the systemic circulation. The lipophilic cell membrane offers a preferable route 
for lipophilic drugs compared to hydrophilic compounds [1]. Drugs can transverse both 
pathways simultaneously although one route could be predominant depending on the 
physicochemical properties of the drug [31].   
 
Figure 3: Schematic representation of different route of drug permeation 
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Although passive diffusion is the predominant mechanism of absorption from the oral 
mucosa, specialized transport mechanisms have also been reported for a few drugs and 
nutrients. Study by Kurosaki and co-workers [45] reported that the rate of absorption of D-
glucose from the dorsal and ventral surface of the tongue was significantly greater than that 
of L-glucose, which indicated the occurrence of some specialized transport mechanism. In 
addition, the existence of sodium-dependant D-glucose transport system was reported across 
stratified cell layer of human oral mucosal cells [46]. Table 5 provides examples of several 
drugs transported via different mechanisms across the buccal mucosa. 
Table 5: Examples of drug transported via different mechanisms through buccal mucosa. 
 
Name of Drug Transport mechanism Path way Tissue References 
5-Aza-2‟-
deoxycytidine 
Passive  Not defined Buccal mucosa 40 
2‟, 3‟ –
dideoxycytidine 
Passive  Not defined Buccal mucosa 41 
Flecainide Passive Paracellular Buccal mucosa 42 
Sotalol Passive Paracellular Buccal mucosa 42 
Nicotine Passive Paracellular, 
Transcellular 
TR146 Cell culture 
and buccal 
43 
Lamotrigine Passive Transcellular Buccal 44 
Galantamine Passive Not defined Human oral 
epithelium and 
buccal mucosa 
47 
Naltrexone Passive Not defined Buccal mucosa 48 
Buspirone Passive Transcellular Buccal mucosa 49 
Ondansatron HCl Passive Not defined Buccal mucosa 50 
Monocarboxylic 
acids 
Carrier mediated Carrier 
mediated 
Primary cultured 
epithelial cells 
51, 52 
Glucose Carrier mediated Carrier 
mediated 
Buccal, oral 
mucosal cells and 
dorsum of tongue 
53 
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5. Oral transmucosal drug delivery technologies 
Continuous research into the improvement of the oral transmucosal delivery of drugs has 
resulted in the development of several conventional and novel dosage forms like solutions, 
tablets/lozenges, chewing gums, sprays, patches and films, hydrogels, hollow fibres and 
microspheres.  These dosage forms can be broadly classified into liquid, semi-solid, solid or 
spray formulations [54]. Oral transmucosal systems for systemic drug delivery are usually 
designed  to deliver the drug for either i)  rapid drug release for immediate and quick action, 
ii) pulsatile release with rapid appearance of drug into systemic circulation and subsequent 
maintenance of drug concentration within therapeutic profile or iii) controlled release for 
extended period of time (as depicted in Figure 4).  
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Figure 4: Schematic representation of different type of mucosal drug delivery system 
Several companies are currently engaged in development and commercialization of drug 
delivery technologies based on oral transmucosal systems. Table 6 shows the list of products 
commercially approved for oral transmucosal administration. The list of companies currently 
engaged in developing technology platforms for oral transmucosal drug delivery system is 
shown in Table 7.  The majority of the commercially available formulations are solid dosage 
forms such as tablets and lozenges. A few companies have had successes in developing 
technology platforms for films or patches with most aimed at achieving rapid drug release 
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and clinical response. The limitations associated with such type of dosage forms include 
uncontrolled swallowing of released drug into GI tract and difficulties in holding the dosage 
form at the site of absorption. These are the areas where more research focus is required, 
especially using mucoadhesive systems. 
Table 6: Commercially available oral transmucosal drug delivery systems [35] 
Drug Dosage 
form 
Type of 
release 
Product Name Manufacturer 
Fentanyl citrate Lozenge Quick Actiq Cephalon 
 Tablet Quick Fentora Cephalon 
 Film Quick Onsolis Meda Pharmaceutical Inc. 
Buprenorphine 
HCl 
Tablet Quick Subutex Reckitt Benckiser 
Buprenorphine 
HCl  and  
naloxone 
HCl 
Tablet Quick Suboxane Reckitt Benckiser 
Proclorperazine Tablet Controlled Buccastem Reckitt Benckiser 
Testosterone Tablet Controlled Striant SR Columbia Pharmaceuticals 
Nitroglycerine Tablet, 
Spray 
Quick Nitrostat W Lambert-P Davis-Pfizer 
Pharmaceuticals 
Glyceryl trinitrate Spray Quick Nitromist NovaDel 
 
Zolpidem Spray Quick Zolpimist NovaDel 
 Tablet Quick Suscard Forest Laboratories 
Nicotine Chewing 
gum 
Quick Nicorette GSK Consumer Health 
 Lozenge Quick Nicotinelle Novartis Consumer Health 
Miconazole Tablet Quick Loramyc BioAlliance Pharma SA 
Cannabis-derived Spray Quick Sativex GW Pharmaceuticals, PLC 
Insulin Spray Quick Oral-lyn Generex Biotechnology 
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Table 7: List of companies with their technology platforms based on oral transmucosal 
system 
Company Technology References 
IntelGenx VersaFilm (Quick release wafer 
technology) 
55 
Bioenvelop Thinsol (edible film technology) 56 
HealthSport and InnoZen Bilayer film-strip 57 
BioFilm Dissolvable thin film 58 
Meldex XGel (Films), SoluLeaves (Films), 
WaferTab (Film strip), OraDisc 
(disc) 
59 
Uluru Inc OraDisc (disc) 60-62 
MonoSol Rx MonoSol Rx thin film 63 
Passion for Life Healthcare Snoreeze Oral strips 64, 65 
GW Pharma Sativex Buccal Spray 66 
Generex Biotechnology Oral spray (RapidMist) technology 67 
 MetControl chewing gum 67 
NovaDel Novamist spray technology 68 
Biodelivery Sciences 
International (BDSI) 
BEMA technology 69, 70 
Transcept Pharmaceutical Inc. Sublingual tablets 71 
Labtec Pharma RapidFilm technology 72-75  
MedPharm Ltd MedRo  mucoadhesive spray 
technology 
76 
 
5.1 Mucoadhesive systems 
Other than the low surface area available for drug absorption in the buccal cavity, the 
retention of the dosage form at the site of absorption is another factor which determines the 
success or failure of buccal drug delivery system. The utilization of mucoadhesive systems is 
essential to maintain an intimate and prolonged contact of the formulation with the oral 
mucosa allowing a longer duration for absorption. Some adhesive systems deliver the drug 
towards the mucosa only with an impermeable product surface exposed to the oral cavity 
which prevents the drug release into oral cavity [77]. For example, Lopez and co-workers 
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[78] designed bilaminated films to provide unidirectional release of drug and avoid buccal 
leakage. They contained a bioadhesive layer made up of chitosan, polycarbophil, sodium 
alginate and gellan gum while backing layer made up of ethyl cellulose. 
5.1.1 Theories of mucoadhesion 
The most widely investigated group of mucoadhesives used in buccal drug delivery systems 
are hydrophilic macromolecules containing numerous hydrogen bond-forming groups [79]. 
The presence of hydroxyl, carboxyl or amine groups on the molecules favours adhesion. 
They are called „wet‟ adhesives as they are activated by moistening and will adhere non-
specifically to many surfaces. Unless water uptake is restricted, they may over hydrate to 
form slippery mucilage. For dry or partially hydrated dosage forms two basic steps in 
mucoadhesion have been identified [80]. Step one is the „contact stage‟ where intimate 
contact is formed between the mucoadhesive and mucous membrane. Within the buccal 
cavity the formulation can usually be readily placed into contact with the required mucosa 
and held in place to allow adhesion to occur. Step two is the „consolidation‟ stage where 
various physicochemical interactions occur to consolidate and strengthen the adhesive joint, 
leading to prolonged adhesion.  
Mucoadhesion is a complex process and numerous theories have been presented to explain 
the mechanisms involved. These theories include mechanical-interlocking, electrostatic, 
diffusion- interpenetration, adsorption and fracture processes [81], whilst undoubtedly the 
most widely accepted theories are founded upon surface energy thermodynamics and 
interpenetration/diffusion [82]. The wettability theory is mainly applicable to liquid or low 
viscosity mucoadhesive systems and is essentially a measure of the spreadability of the drug 
delivery system across the biological substrate [83]. The electronic theory describes adhesion 
occurs by means of electron transfer between the mucus and the mucoadhesive system arising 
through differences in their electronic structures. The electron transfer between the mucus 
and the mucoadhesive results in the formation of a double layer of electrical charges at the 
mucus and mucoadhesive interface. The net result of such a process is the formation of 
attractive forces within this double layer [84]. According to fracture theory, the adhesive 
bond between systems is related to the force required to separate both surfaces from one 
another. This „„fracture theory” relates the force for polymer detachment from the mucus to 
the strength of their adhesive bond. The work of fracture has been found to be greater when 
the polymer network strands are longer or if the degree of cross-linking within such as system 
is reduced [85]. According to adhesion theory, adhesion is defined as being the result of 
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various surface interactions (primary and secondary bonding) between the adhesive polymer 
and mucus substrate. Primary bonds due to chemisorption result in adhesion due to ionic, 
covalent and metallic bonding, which is generally undesirable due to their permanency [86]. 
The diffusion-interlocking theory proposes the time-dependent diffusion of mucoadhesive 
polymer chains into the glycoprotein chain network of the mucus layer. This is a two-way 
diffusion process with penetration rate being dependent upon the diffusion coefficients of 
both interacting polymers [87]. 
5.1.2 Polymers for mucoadhesive systems 
The polymeric attributes that are pertinent to high levels of retention at applied and targeted 
sites via mucoadhesive bonds include hydrophilicity, negative charge potential and the 
presence of hydrogen bond forming groups. Additionally, the surface free energy of the 
polymer should be adequate so that „wetting‟ with the mucosal surface can be achieved. The 
polymer should also possess sufficient flexibility to penetrate the mucus network, be 
biocompatible, non-toxic and economically favourable [88]. According to the literature 
mucoadhesive polymers are divided into first generation mucoadhesive polymers and second 
generation novel mucoadhesive polymers. The first generation polymers are divided into 
three major groups according to their surface charges which include anionic, cationic and 
non-ionic polymers. The anionic and cationic polymers exhibit stronger mucoadhesion [89]. 
Anionic polymers are the most widely employed mucoadhesive polymers within 
pharmaceutical formulations due to their high mucoadhesive functionality and low toxicity. 
Such polymers are characterised by the presence of carboxyl and sulphate functional groups 
that give rise to a net overall negative charge at pH values exceeding the pKa of the polymer. 
Typical examples include polyacrylic acid (PAA) and its weakly cross-linked derivatives and 
sodium carboxymethyl cellulose (Na CMC). PAA and Na CMC possess excellent 
mucoadhesive characteristics due to the formation of strong hydrogen bonding interactions 
with mucin [90]. Among the cationic polymer systems, undoubtedly chitosan is the most 
extensively investigated within the current scientific literature [91]. Chitosan is a cationic 
polysaccharide, produced by the deacetylation of chitin, the most abundant polysaccharide in 
the world, next to cellulose [91]. Chitosan is a popular polymer to use due to its 
biocompatibility, biodegradability and favourable toxicological properties [92]. Chitosan has 
been reported to bind via ionic interactions between primary amino functional groups and the 
sialic acid and sulphonic acid substructures of mucus [93]. The major benefit of using 
chitosan within pharmaceutical applications has been the ease with which various chemical 
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groups may be added, in particular to the C-2 position allowing for the formation of novel 
polymers with added functionality. Using such modifications, the properties of chitosan may 
be tailored to suit the requirements of specific pharmaceutical–technological challenges [94] 
although this often results in additional regulatory requirements as it becomes a new 
excipient with all the added problems of qualifying from a safety basis.  
Unlike first-generation non-specific platforms, certain second-generation polymer platforms 
are less susceptible to mucus turnover rates, with some species binding directly to mucosal 
surfaces; more accurately termed „cytoadhesives‟. Furthermore as surface carbohydrate and 
protein composition at potential target sites vary regionally, more accurate drug delivery may 
be achievable [81]. Lectins are naturally occurring proteins that play a fundamental role in 
biological recognition phenomena involving cells and proteins. After initial mucosal cell-
binding, lectins can either remain on the cell surface or in the case of receptor-mediated 
adhesion possibly become internalised via endocytosis [95]. Although lectins offer significant 
advantages in relation to site targeting, many are toxic or immunogenic, and the effects of 
repeated lectin exposure are largely unknown. It is also feasible that lectin-induced antibodies 
could block subsequent adhesive interactions between mucosal epithelial cell surfaces and 
lectin delivery vehicles. Moreover, such antibodies may also render individuals susceptible to 
systemic anaphylaxis on subsequent exposure [95].  
Thiolated polymers (thiomers) are a type of second-generation mucoadhesive derived from 
hydrophilic polymers such as polyacrylates, chitosan or deacetylated gellan gum [96]. The 
presence of thiol groups allows the formation of covalent bonds with cysteine rich sub 
domains of the mucus gel layer leading to increased residence time and improved 
bioavailability [97]. Whilst first-generation mucoadhesive platforms are facilitated via non-
covalent secondary interactions, the covalent bonding mechanisms involved in second- 
generation systems lead to interactions that are less susceptible to changes in ionic strength 
and/or the pH [98].  
5. 2 Dosage forms 
5.2.1 Liquid dosage forms 
Liquid dosage forms include solutions or suspensions made of drug solubilised or suspended 
into suitable aqueous vehicles. Such types of dosage forms are usually employed to exert 
local action into the oral cavity and several antibacterial mouthwashes and mouth-freshener 
are commercially available for this purpose. The limitation associated with these liquid 
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dosage forms are that they are not readily retained or targeted to buccal mucosa and can 
deliver relatively uncontrolled amounts of drug throughout oral cavity. Patel and co-workers 
[99] found that polymers be adsorbed from solution onto buccal cells in vivo. From the wide 
range of polymer solutions screened, chitosan gave the greatest binding, followed by 
methylcellulose, gelatin, carbopol and polycarbophil.  
Drug present in the liquid dosage forms can also been delivered in a more controlled manner 
through the use of iontophoresis techniques, which are well known for the delivery of drugs 
through skin, but have also been investigated for drug delivery across the buccal mucosa. 
Jacobsen [100] studied the iontophoretic drug delivery of atenolol hydrochloride solution 
employing three-chamber permeation cell in vitro. The delivery across porcine buccal 
mucosa increased proportionally to increased initial donor concentration, increased „„on 
time‟‟ of current on/ off ratio and increased current density. Microscopical evaluation of 
hematoxyilin-eosin stained sections of porcine buccal mucosa showed only minute 
morphological alterations after conducting 8 h passive permeation whilst 8 h iontophoretic 
treatment showed disordering of the outer epithelial cell layers; the alterations being more 
pronounced in mucosa from reference chambers than donor chambers. Campisi and co-
workers [101] reported that the iontophoretic buccal drug delivery of naltrexone was a 
promising development as naltrexone appeared in the plasma of pigs within 5-10 min of 
administration and reached to peak around 90 min. After 6 h, the plasma level of naltrexone 
delivered via iontophoresis was higher compared to that of naltrexone delivered 
intravenously. Such findings were explained by the presence of a drug reservoir within the 
buccal mucosa after iontophoresis from which naltrexone released gradually and was 
systemically available.  
5.2.2 Semisolid dosage forms 
Semisolid dosage forms usually include gels, creams and ointments, which are applied 
topically into the mucosal surface for either local or systemic effects. These typically contain 
a polymer and drug plus any required excipient dissolved or suspended as a fine powder in an 
aqueous or non-aqueous base. Hydrogels can also be used in semi-solids for drug delivery to 
the oral cavity. These are formed from polymers and can be hydrated in an aqueous 
environment without dissolution, acting as drug delivery systems by physically entrapping 
molecules, which are then slowly released by diffusion or erosion after gel hydration [102]. 
Semi-solid formulations can be applied using the finger (or syringe) to a target region and 
tend to be more acceptable in terms of mouth feel to patients relative to a solid dosage form. 
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However, they may deliver variable amounts of active ingredients in comparison with a unit 
dosage form [7]. Hydrogels are formed from polymers and may be hydrated in an aqueous 
environment without dissolution, acting as drug delivery systems by physically entrapping 
molecules, which are then slowly released by diffusion or erosion after gel hydration [102]. 
Semisolid systems have the advantage of being deliverable with a syringe, with a consequent 
ease of placement to the periodontal pockets [103] and easy dispersion throughout the 
mucosa of the oral cavity. However, they may deliver variable amounts of active ingredients 
in comparison with a unit dosage form [7]. Another drawback of semi-solid dosage forms 
designed for use in the oral cavity is the poor retention at the site of application especially 
when the hydrogel polymer has no adhesive properties. This drawback can be minimized or 
eliminated by the incorporation of a bioadhesive polymer into the formulation [104]. A 
mucoadhesive gel of risperidone containing Poloxamer 407 and Carbopol 974 was able to 
achieve a steady state flux of 64.85 ± 8.0 µg/cm
2
/h in an in vitro permeation study, which 
was extrapolated to an in vivo plasma concentration of 11.2-56.1 µg/L for mucosal 
application area between 2 and 10 cm
2
. As such and assuming that these predicted plasma 
concentrations are within the therapeutic range of risperidone required in humans, delivery of 
risperidone via the buccal mucosa has potential for treatment of schizophrenia [105]. In 
addition, Perioli and co-workers [106] proposed emulgels (gellified emulsion) made up of 
Pemulin
®
 1621 as polymeric emulsifier and Compritol
®
 888 ATO as an internal oily phase 
for the buccal delivery of flurbiprofen and found that the drug release was controlled with 50-
80 % of drug release within 100 min of application. In addition, the emulgels were reported 
to be retained on human buccal mucosa for an average period of one hour. 
5.2.3 Solid dosage forms 
5.2.3.1 Tablets/Lozenges 
These are solid dosage forms prepared by the compression of powder mixes that can be 
placed into contact with the oral mucosa and allowed to dissolve or adhere depending on the 
type of excipients incorporated into the dosage form. They can deliver drug 
multidirectionally into the oral cavity or to the mucosal surface. Alternatively, the dosage 
form can contain a impermeable backing layer to ensure that drug is delivered 
unidirectionally. Disadvantages of buccal tablets can include patient acceptability (mouth 
feel, taste and irritation) and the nonubiquitous distribution of drug within saliva for local 
therapy [7]. It is important to point out the possible problems that children and the elderly 
may experience with the use of adhesive tablets which include the possible discomfort 
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provoked by the material applied to the mucosa and the possibility of the dosage form 
separating from the mucosa, being swallowed, and then adhering to the wall of the 
esophagus. A typical bioadhesive formulation of this type consists of a bioadhesive polymer 
(such as polyacrylic acids or a cellulose derivative), alone or in combination, incorporated 
into a matrix containing the active agent and excipients, and perhaps a second impermeable 
layer to allow unidirectional drug delivery [107, 108].  
 
Figure 5: Schematic representation of different types of matrix tablets designed for buccal 
drug delivery system (Adapted from Caramella and co-workers [108]). 
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Amongst the different types of formulation available on the market, solid dosage forms have 
probably been developed the most extensively such as the nitroglycerin sublingual tablet, 
fentanyl lozenge on a stick and prochlorperazine buccal tablets. The limitation of these drug 
delivery systems is the short residence time at site of absorption as depending on the size and 
type of formulation; they usually dissolved within 30 min, thus limiting the total amount of 
drug that can be delivered. The dissolution or disintegration of lozenges is usually controlled 
by the patient, i.e. how hard they suck the unit. Increased sucking and saliva production 
causes uncontrolled swallowing and loss of drug down the GI tract. Thus, solid dosage forms 
generally have a much higher inter- and intra-individual variations in absorption and 
bioavailability. Also such types of system are not able to provide unidirectional release of 
drug. Continuous secretion of saliva is another major hurdle to the performance of such 
dosage form. 
Minghetti and co-workers [109] proposed the utilisation of clobetasol-17 propionate 
mucoadhesive tablets for the treatment of oral litchen planus. In this formulation, HPMC and 
MgCl2 were added into a mucoadhesive polymer matrix, i.e. poly(sodium methacrylate 
methylmethacrylate), to modify the tablet erosion rate and to obtain drug  release over a 6 h 
period. A double-blind, controlled study was performed using three groups of patients (n = 
16) who received three applications-a-day over 4 weeks of the developed clobetasol-17 
propionate tablets, placebo tablets or a commercial clobetasol-17 propionate ointment for 
cutaneous application (123 µg/application) combined with Orabase™. The application of 24 
µg clobetasol-17 propionate tablet three times a day appeared to be more effective and safer 
than the semisolid preparation. The addition of HPMC and MgCl2 in the formulation was 
thought to effectively control tablet hydration/erosion and, consequently drug release, without 
significantly modifying mucoadhesion.  
Pillay and co-worker [110] reported the use of porosity enabled matrix tablets for the 
sustained delivery of phenytoin sodium as a model drug.  The porosity (pore structure, 
interconnectors, pore width or diameter, and pore volume of distribution) of the porosity 
enable matrix formulations had a significant impact on their physicochemical properties. 
Interphase, co-particulate, co-solvent, homogenization coupled with lyophilization, proved to 
be efficient methods for construction of the formulation. The optimized formulation 
displayed the potential to consistently release drug in a steady state, controlled manner over 8 
h. Furthermore, the formulation showed the capability to consistently initiate and sustain the 
permeation of drug through the model buccal mucosal tissue over the period of 8 h. 
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The work reported by Kramer and Flynn [111] on pH-solubility profile showed that it is 
possible to saturate simultaneously unionized and ionized drug species at particular pH called 
pHmax which should lead to an increased transbuccal permeability compared to any other pH. 
Chow and co-workers [112] explored a pHmax concept for the sublingual delivery of 
propanolol. A buffered sublingual propranolol tablet, designed to achieve its pHmax (when 
dissolved in saliva), was compared to a marketed product (Inderal® which could not achieve 
pHmax) in 8 healthy human volunteers. Each subject received the products sublingually for 15 
min followed by swallowing the remaining drug in saliva. The plasma propranolol AUC 
during the first 30 min from the buffered tablet were significantly higher than that from the 
Inderal® tablet (p<0.05). No significant differences in the remaining AUC were observed.  
Disks are similar to tablets but are thinner and more flat in shape and can be developed into a 
different size and shape more suitable to be placed into the buccal cavity. An in vivo 
evaluation of a buccal disk of cetylpyridinium chloride revealed adequate comfort, taste, non-
irritancy and none of the volunteers reported severe dry mouth/severe salivation or heaviness 
at the place of attachment. Salivary concentrations were maintained above the MIC for 8 h. A 
good correlation was found between the drug concentration in situ and concentration of drug 
in saliva collected from healthy human volunteers [113]. A buccal disk of oxycodone 
hydrochloride was evaluated in healthy human volunteers. The Tmax data obtained was greater 
for the buccoadhesive disks compared to other oral tablets. The fact that the AUC and Cmax 
values were comparable to conventional tablets may have been due to the lack of a backing 
layer for buccal disk [114]. Thiocochicoside has also been explored for use on the disk type 
delivery system. An in vivo thiocolchicoside absorption experiments indicated that the fast 
dissolving sublingual form resulted in a quick uptake of drug within 15 min whereas for the 
adhesive buccal form the same dose was absorbed over an extended period of time [115]. 
5.2.3.2 Patches/Films/Wafers 
These dosage forms are usually prepared by casting a solution of the polymer, drug and any 
excipients (such as a plasticiser) on to a surface and allowing it to dry. Patches can be made 
10-15 cm
2
 in size but are more usually 1-3 cm
2
 with perhaps an ellipsoid shape to fit 
comfortably into the centre of the buccal mucosa. In a similar fashion to buccal tablets, they 
can be made multidirectional or unidirectional (e.g., by the application of an impermeable 
backing layer). They have many of the advantages and disadvantages of buccal tablets, but by 
being thin and flexible, tend be less obtrusive and more acceptable to the patient. The relative 
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thinness of the films, however, means that they are more susceptible to overhydration and 
loss of the adhesive properties [7].  
The major method of polymeric film manufacture is the solvent evaporation process, in 
which the polymeric material, with or without plasticizer, is dissolved in a solvent or solvent 
mixture and into which the active constituent is dissolved or dispersed. This solution is then 
cast onto a suitable substrate and the solvent is allowed to evaporate, leaving a solid 
polymeric film containing the drug. These types of dosage forms have also been prepared 
using other techniques such as direct compression and hot-melt extrusion. The advantage 
associated with these types of techniques was the need organic solvent is avoided and thus it 
proves to be environment friendly. 
The oral cavity mucosa is an ideal surface for the placement of retentive delivery systems 
such as patches, since it contains a large expanse of smooth and immobile tissue. 
Mucoadhesive patches for administration to the mucosa of the oral cavity may have a number 
of different designs, depending on various considerations, such as the therapeutic aim and the 
physicochemical and pharmacokinetic properties of the active ingredient. Two different 
rationales for developing mucosal patches may be considered: patches can be intended to 
deliver a drug to the systemic circulation in a way that is superior to other routes of 
administration, or their purpose may be local therapy of the oral mucosa [107].  
Mucoadhesive buccal patches of lidocaine produced aneasthesia throughout the adhesion 
period of 60-120 min and the patch was not detached from the buccal mucosa [116].  In a 
study by Ismail and co-workers [117], it was found that the in vivo release of miconazole was 
quick but transient from the commercial oral gel Daktarin
®
, which diminished sharply after 
the first hour of application, compared to buccal patches of miconazole (Figure 6). The 
optimum patch formulation comprised PVA and PVP and exhibited sustained release over 5 
h. Although high drug levels were observed for both formulations during the first 30 min of 
the experiment, a remarkable drug concentration was released from the patch after 4 h 
compared to traces of the drug obtained from the commercial gel. Detectable drug 
concentrations were present in saliva even after the complete erosion of the patch (4-4.5 h). 
The minimum inhibitory concentrations (MIC) for miconazole nitrate against C. albicans is 5 
µg/ml; T
>MIC
 is the time where the last salivary concentration is above the MIC. The recorded 
values of T
>MIC
 were 1.3 and 6.1 h for Daktarin
®
 oral gel and for mucoadhesive patch, 
respectively. It is clear that the mucoadhesive patch had a greater ability to sustain an 
elevated drug concentration in saliva despite the administration of a smaller dose (10 mg) 
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compared with the gel (25 mg). In another study in human volunteers by Ismail and co-
workers [118], a cetylpyridinum chloride patch made up of chitosan was shown to be 
superior to a patch made up of hydroxyethyl cellulose and polyvinyl alcohol in terms of in 
vivo buccal residence time though none of the polymeric patches were detached from the 
mucosa during the study. 
 
Figure 6: Mean salivary miconazole concentration obtained in vivo with mucoadhesive patch 
(o) and Daktarin
®
 oral gel (●). The insert represents correlation between in vitro/in vivo 
cumulative miconazole concentration (µg/ml) released from the mucoadhesive patch 
[Adapted from ref. 117]. 
Bilayer films have been evaluated for the mucosal immunization of rabbit via the buccal 
route. The film consists of two layer and among them one made up of impermeable backing 
layer while the another layer consists of drug facing towards the mucosa. Efficacy of 
immunization has been compared by administering the protein injection by subcutaneous 
route. Postloaded plasmid DNA and β-lactosidase proteins remained stable after being 
released from bilayer films. Buccal immunization using novel bilayer films containing 
plasmid DNA led to comparable antigen-specific IgG titer to that of subcutaneous protein 
injection. All rabbits immunized with plasmid DNA via the buccal route but none by the 
subcutaneous route with protein antigen, demonstrated splenocyte proliferative immune 
responses. The authors concluded that the vaccination without the use of needles would 
provide a distinct advantage in terms of both cost and safety over conventional vaccines that 
must be given with needles [119].  
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The current literature shows the research is more focused towards the mucoadhesive type of 
films or patches which contain different mucoadhesive components to extend the residence 
time of dosage forms at the site of application. Table 8 shows list of the drugs explored in 
such mucoadhesive systems. 
Table 8: List of few drugs with clinical outcome for films type of buccal drug delivery system 
Drug Polymers Techniques Dosage 
Form 
Clinical outcomes References 
Lidocaine HCl EC, HPC  Solvent 
casting 
Film Effect of drug 
observed throughout 
adhesion of dosage 
form 
116 
Miconazole 
nitrate 
Na CMC, HEC, 
HPMC, PVP 
Solvent 
casting 
Film Uniform and effective 
salivary levels for 
atleast 6 h 
117 
Cetylpyridinum 
chloride  
PVA, HEC, 
chitosan 
Solvent 
casting 
Patch Increase in residence 
time and decrease in 
drug release with 
storage  
118 
Acyclovir Chitosan HCl, 
PAA 
Solvent 
casting 
Film Increase permeation 
compared to cream 
and suspension 
120 
Calcitonin Noveon AA1, 
Eudragit S100  
Solvent 
casting 
Bilayer 
film 
Relative 
bioavailability of 43.8 
± 10.9% in rabbit 
121 
Clotrimazole HPC, PEO Hot melt 
extrusion 
Film Excellent content 
uniformity and post 
processing drug 
content of 93.3% 
122 
Sumatriptan 
succinate 
Chitosan, gelatin, 
PVP 
Solvent 
casting 
Bilayer 
patch 
No mucosal damage 
confirmed by 
histopathological 
study 
123 
EC is ethyl cellulose, HPC is hydroxypropyl cellulose, Na CMC is sodium carboxymethyl 
cellulose, HEC is hydroxyethyl cellulose, HPMC is hydroxypropyl methylcellulose, PVP is 
polyvinyl pyrrolidone, PVA is polyvinyl alcohol, PAA is polyacrylic acid and PEO is 
polyethylene oxide. 
5.2.3.3 Micro/nano-particulates 
These are typically delivered as an aqueous suspension but can also be applied by aerosol or 
incorporated into a paste or ointment. Particulates have the advantage of being relatively 
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small and, therefore, more likely to be acceptable to the patient. However, the dose of drug 
retained on the buccal mucosa and, therefore, delivered may not be consistent relative to a 
single-unit dosage form such as a patch or buccal tablet. Polymeric microparticles (23-38 μm) 
of Carbopol
®
, polycarbophil, chitosan or Gantrez
®
 were found to be capable of adhering to 
porcine oesophageal mucosa, with particles prepared from the polyacrylic acids exhibiting 
greater mucoadhesive strength during tensile testing studies whereas, in „elution‟ studies, 
particles of chitosan or  Gantrez were seen to persist on mucosal tissue for longer periods of 
time [124, 125]. Holpuch and co-workers [126] explored the use of nanoparticles for local 
delivery to the oral mucosa. Two types of nanoparticles were studied in a proof of concept 
study which were solid lipid nanoparticles incorporating either idarubicin or BODIPY
®
 FL 
C12 as model fluorescent probes and polystyrene nanoparticles (FluoSpheres
®
) in monolayer-
cultured human oral squamous cell carcinoma (OSCC) cell lines and normal human oral 
mucosal explants. The results demonstrated that OSCC cells internalized solid lipid 
nanoparticles. The observed penetration of nanoparticles through the epithelium and 
basement membrane into the underlying connective tissue suggested the possibility of oral 
transmucosal nanoparticle delivery for systemic therapy. Monti and co-workers [127] 
produced an atenolol containing microsphere using Poloxamer 407 and evaluated the 
formulation in vivo in rabbits against marketed tablet formulation as a reference. After 
administration of the microsphere formulations, the atenolol concentration remained higher 
than the reference tablet during the entire elimination phase showing a sustained release 
profile from the microspheres; the concentrations at 24 h were 0.75 ± 0.1 µg /ml vs 0.2 ± 0.1 
µg /ml for the microspheres and marketed tablet, respectively. Moreover, the absolute 
bioavailability of microsphere formulations was higher than that of reference tablets in spite 
of a lower drug dose in the former, suggesting a possible dose reduction by atenolol 
microparticles via orotransmucosal administration. 
Intra-orally fast-dissolving particles of perphenazine (PPZ) were reported by Laitinen and co-
workers [128]. Freeze-drying of solutions of a poorly water soluble drug PPZ with 0%, 20%, 
80% or 95% of a polyethylene glycol (PEG) led to an improved PPZ solubility and extremely 
fast dissolution rate in a small liquid (pH 6.8) volume compared to crystalline or micronized 
PPZ. The most remarkable improvement in the dissolution rate was seen with 1: 5 ratio of 
PPZ to PEG, which dissolved within one minute without precipitation of the supersaturated 
PPZ. A solid dispersion of PPZ with β-CD prepared by spray drying and with PEG 8000 
prepared by freeze drying were compared with micronized PPZ for pharmacokinetic 
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parameters in the rabbit after sublingual administration [129]. The value for area under the 
curve from 0 to 360 min (AUC0-360 min) of perphenazine after peroral administration was only 
8% compared to the AUC0-360 min value obtained after intravenous administration, while the 
corresponding values for the sublingually administered formulations were 53% 
(perphenazine/PEG 8000 solid dispersion), 41% (perphenazine/β-CD complex) and 64% 
(micronized perphenazine). These results revealed that the micronized PPZ despite having 
lower solubility compared to its solid dispersion showed improved plasma concentration. 
This may have been due to the viscosity enhancing effect of PEG at site of absorption or it 
may be that the absorption was not solubility or dissolution rate limited. 
Liposomes are one of the alternatives for drugs which are poorly soluble and hence are not 
efficiently delivered from a solid dosage form. For example, silamyrin liposomal buccal 
delivery showed steady state permeation through a chicken buccal pouch for 6 h and was 
higher compared to free drug powder [130].  
5.3.4 Sprays 
An aerosol spray is one of the suitable alternatives to the solid dosage forms and can deliver 
the drug into the salivary fluid or onto the mucosal surface and thus is readily available for 
the absorption. As the spray delivers the dose in fine particulates or droplets, the lag time for 
the drug to be available for the site of the absorption is reduced. For example, a 
pharmacokinetic study of buccal insulin spray in patient with Type I diabetes revealed no 
statistical difference in glucose, insulin and C-peptide plasma level compared to insulin 
administered subcutaneously [131]. In a study by Xu and co-workers [132], insulin delivered 
through a novel insulin buccal spray was passed through the buccal mucosa promoted by the 
soybean lecithin and propanediol. Results of rabbit and rat experiments revealed that insulin 
delivered through the buccal spray is an effective therapeutic alternative to current 
medication system for treating diabetes. Generex‟s Oral-lynTM is a oral spray for insulin for 
the treatment of diabetes I and II which is based on the RapidMist
TM
 technology platform. 
Generex Oral-lyn™ is reported to be safe, simple, fast, effective, and pain-free alternative to 
subcutaneous injections of prandial insulin and is conveniently delivered to the membranes of 
the oral cavity by a simple asthma-like device with no pulmonary (lung) deposition [133]. 
Fentanyl citrate, morphine and low molecular weight heparin are also in clinical development 
based on RapidMist
TM
 technology by Generex [67]. 
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6. Conclusion 
Due to the ease of access and avoidance of the hepatic metabolism, oral transmucosal drug 
delivery offers a promising alternative to overcome the limitations of conventional oral drug 
delivery and parental administration. The buccal and sublingual routes, in particular, present 
favourable opportunities and many formulation approaches have been explored for such an 
application; although the current commercially available formulations are mostly limited to 
tablets and films. Oral mucoadhesive dosage forms will continue be an exciting research 
focus for improving drug absorption especially for the new generation of the so called 
„biologics‟, although, the palatability and irritancy and formulation retention at the site of 
application need to be considered in the design of such medicines.  
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